Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Med Sci (Basel) ; 12(2)2024 Apr 24.
Artigo em Inglês | MEDLINE | ID: mdl-38804379

RESUMO

BACKGROUND: Cancer-therapy-related cardiac dysfunction (CTRCD) is a growing concern for public health, with a growing incidence due to improved survival rates of patients with hematological malignancies due to diagnostic and therapeutic advances. The identification of patients at risk for CTRCD is vital to developing preventive strategies. METHODS: A single-center retrospective cohort study was conducted between 1 January 2017 and 15 February 2023. Medical records of patients with lymphoma treated with first-line anthracyclines were reviewed. Demographic data, cardiovascular risk factors, biomarkers of myocardial damage, and echocardiographic information were collected. RESULTS: A total of 200 patients were included. The incidence of CTRCD was 17.4% (35/200). Patients with CTRCD were older than those without CTRCD, with a mean age of 65.17 years vs. 56.77 (p = 0.008). Dyslipidemia (DL) (31.4% vs. 13.4% p = 0.017) and previous cardiovascular disease (40% vs. 13.3%; p < 0.001) were more frequent in the group who developed an event. Mean baseline NT-proBNP levels in the subgroup with cardiovascular events were 388.73 kg/L ± 101.02, and they were 251.518 kg/L ± 26.22 in those who did not (p = 0.004). Differences in Troponin I levels were identified during and after treatment without exceeding the laboratory's upper reference limit. Patients were followed for a median of 51.83 months (0.76-73.49). The presence of a CTCRD event had a negative impact on overall mortality from any cause (HR = 2.23 (95% CI: 1.08-2.93); p = 0.031). CONCLUSIONS: Early identification of risk factors is crucial to manage patients at risk for CTRCD.


Assuntos
Antraciclinas , Doenças Cardiovasculares , Linfoma , Humanos , Antraciclinas/efeitos adversos , Antraciclinas/uso terapêutico , Masculino , Feminino , Idoso , Pessoa de Meia-Idade , Estudos Retrospectivos , Doenças Cardiovasculares/induzido quimicamente , Linfoma/tratamento farmacológico , Fatores de Risco , Cardiotoxicidade , Incidência
2.
Pacing Clin Electrophysiol ; 33(4): 497-507, 2010 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-20059709

RESUMO

Cardiac anatomy is complex and its understanding is essential for the interventional arrhythmologist. The first difficulty is the terminology used to describe the location of sites of mapping and ablation. For many years, electrophysiologists have named these positions following the conventional electrocardiographical vocabulary, or the terminology used by surgeons performing arrhythmic surgery. This traditional nomenclature, however, failed to take note of the crucial principle of considering the location of the heart in the human body as viewed in its erect position. In other words, it had failed to use an attitudinally appropriate terminology. Almost 10 years ago, a new attitudinal nomenclature was proposed for the right and left atrioventricular junctions. In this first of a series of reviews of cardiac anatomy as seen by the interventional arrhythmologist, we discuss the role of attitudinally appropriate terminology, and relate this to the projections used for cardiac fluoroscopy, fluorography, and angiography. Throughout our series of reviews, we will illustrate the value of The Visible Human Slice and Surface Server in facilitating the understanding of the fluoroscopic anatomy. (PACE 2010; 497-507).


Assuntos
Arritmias Cardíacas/fisiopatologia , Coração/anatomia & histologia , Coração/diagnóstico por imagem , Ablação por Cateter , Angiografia Coronária , Fluoroscopia , Sistema de Condução Cardíaco/anatomia & histologia , Sistema de Condução Cardíaco/diagnóstico por imagem , Humanos , Modelos Anatômicos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA